143 related articles for article (PubMed ID: 37630828)
1. Calorie Restriction Impairs Anti-Tumor Immune Responses in an Immunogenic Preclinical Cancer Model.
Dung NT; Susukida T; Ucche S; He K; Sasaki SI; Hayashi R; Hayakawa Y
Nutrients; 2023 Aug; 15(16):. PubMed ID: 37630828
[TBL] [Abstract][Full Text] [Related]
2. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
3. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Ji S; Lee J; Lee ES; Kim DH; Sin JI
Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
[TBL] [Abstract][Full Text] [Related]
4. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
5. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
6. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
[TBL] [Abstract][Full Text] [Related]
7. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
8. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
9. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
10. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
11. mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model.
Sittplangkoon C; Alameh MG; Weissman D; Lin PJC; Tam YK; Prompetchara E; Palaga T
Front Immunol; 2022; 13():983000. PubMed ID: 36311701
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
13. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
14. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
16. Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response.
Stirling ER; Terabe M; Wilson AS; Kooshki M; Yamaleyeva LM; Alexander-Miller MA; Zhang W; Miller LD; Triozzi PL; Soto-Pantoja DR
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36418073
[TBL] [Abstract][Full Text] [Related]
17. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
18. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
19. Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma.
Pinjusic K; Dubey OA; Egorova O; Nassiri S; Meylan E; Faget J; Constam DB
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580932
[TBL] [Abstract][Full Text] [Related]
20. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]